Dimensional Fund Advisors LP Decreases Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Dimensional Fund Advisors LP cut its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 40.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 99,578 shares of the company's stock after selling 66,569 shares during the quarter. Dimensional Fund Advisors LP owned 0.10% of Dyne Therapeutics worth $2,346,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in Dyne Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock worth $44,476,000 after buying an additional 27,916 shares during the period. Norges Bank purchased a new position in Dyne Therapeutics during the fourth quarter worth $22,384,000. Charles Schwab Investment Management Inc. boosted its stake in Dyne Therapeutics by 2.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 667,452 shares of the company's stock worth $15,725,000 after buying an additional 18,800 shares during the period. Candriam S.C.A. boosted its stake in Dyne Therapeutics by 2.7% during the fourth quarter. Candriam S.C.A. now owns 401,395 shares of the company's stock worth $9,457,000 after buying an additional 10,439 shares during the period. Finally, Pictet Asset Management Holding SA boosted its stake in Dyne Therapeutics by 6.2% during the fourth quarter. Pictet Asset Management Holding SA now owns 323,552 shares of the company's stock worth $7,623,000 after buying an additional 18,847 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on DYN shares. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price for the company. Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. JPMorgan Chase & Co. lowered their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Chardan Capital reissued a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 9th. Finally, Piper Sandler lowered their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Dyne Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $46.85.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 6,237 shares of company stock worth $77,760 over the last three months. 14.14% of the stock is owned by corporate insiders.

Dyne Therapeutics Stock Up 0.8%

Shares of DYN stock traded up $0.09 on Friday, hitting $11.83. The stock had a trading volume of 2,185,589 shares, compared to its average volume of 1,679,246. The business has a 50 day moving average price of $10.36 and a 200 day moving average price of $17.43. The company has a market cap of $1.34 billion, a PE ratio of -3.32 and a beta of 1.19. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.